Assess whether pediatric studies are necessary or waivable (91469d)

Situation

Biosimilar analytical similarity report arrived with a pediatric ethicist objecting to the proposed design for RWE evidence-strategy director. That is a Pharma & Life Sciences CMC and Development Pathways decision on pediatric studies are necessary in a biologics company planning a biosimilar pathway.

Decision

RWE evidence-strategy director in a biologics company planning a biosimilar pathway must choose Pediatric studies are necessary / Waivable using biosimilar analytical similarity report after a pediatric ethicist objecting to the proposed design.

Hypotheses to test

• Biosimilar analytical similarity report reads as Pediatric studies are necessary once a pediatric ethicist objecting to the proposed design is lined up to the same Pharma & Life Sciences population.
• Biosimilar analytical similarity report is closer to Waivable after a pediatric ethicist objecting to the proposed design; Pediatric studies are necessary would over-claim this CMC and Development Pathways extract.
• A dual reading is still live in biosimilar analytical similarity report for RWE evidence-strategy director in a biologics company planning a biosimilar pathway.
• Biosimilar analytical similarity report is missing the fact RWE evidence-strategy director needs after a pediatric ethicist objecting to the proposed design; stop this Pharma & Life Sciences close.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in biosimilar analytical similarity report after a pediatric ethicist objecting to the proposed design.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on pediatric studies are necessary.
• For this Pharma & Life Sciences CMC and Development Pathways file, read biosimilar analytical similarity report against a pediatric ethicist objecting to the proposed design and write the one fact that would move pediatric studies are necessary for RWE evidence-strategy director.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / CMC and Development Pathways packet (biosimilar analytical similarity report after a pediatric ethicist objecting to the proposed design). The follow-on CMC and Development Pathways action is what RWE evidence-strategy director does next: implement the option, assign an owner, and log the missing fact.